Monoclonal Antibodies
Rituxan® is the brand marketing name of the monoclonal
Spectrum Pharmaceuticals is reporting results from a randomized study pitting the company's
FDA Approves the Removal of the Bioscan Requirement for ZEVALIN® Treatment
HENDERSON,
At the 17th Congress of the European Hematology Association (EHA), biopharmaceutical company
Spectrum Pharmaceuticals will be presenting five study abstracts related to Zevalin, the company
Spectrum Pharmaceuticals is launching a new patient campaign surrounding the company's lead
Spectrum Pharmaceuticals has announced that it intends to acquire the international
Convinced by a steady stream of research, the U.K.'s National Institute for Health and Clinical
According to research presented at the annual meeting of the American Society of Hematology,
According to a recent randomized controlled trial, rituximab increased the duration of remission
The drug Rituximab is showing to slow symptoms of lymphoma, but does it increase survival: